Of late, the exports have shifted in favour of regulated markets evidently as there has been an increase in the share of these markets to about 49% in 2013-14 from about 43% in 2008-09, the Assocham-Yes Bank joint study said.
"India's bulk drug exports are likely to grow at a CAGR of 12-14% till 2018-19, driven largely by exports to regulated markets," The Associated Chambers of Commerce and Industry of India added.
More From This Section
The study also said that the domestic formulations market is likely to cross $20 billion mark by 2018-19 from a level of about $11 billion in 2013-14.
"The growth story of domestic formulations market is expected to remain strong, led by better healthcare diagnostic infrastructure," it added.